NCT05065775View on ClinicalTrials.gov

Bioavailability of Intranasal Dexmedetomidine

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

December 31, 2021

Study Completion Date

May 10, 2022

Conditions
PharmacokineticsArthritis KneeArthritis of HipAnesthesia
Interventions
DEVICE

Dexmedetomidine

Single intranasal dexmedetomidine dose of 100 µg. Intranasal dexmedetomidine will be administered shortly after induction of anesthesia using a mucosal atomization devise (LMA MAD Nasal™)

Trial Locations (1)

Unknown

Perioperative Services, Intensive Care and Pain Therapy, Turku University Hospital and University of Turku, Turku

All Listed Sponsors
lead

Turku University Hospital

OTHER_GOV

NCT05065775 - Bioavailability of Intranasal Dexmedetomidine | Biotech Hunter | Biotech Hunter